Regeneron
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
FDA review for Sanofi and Regeneron’s biologic arthritis drug
January 8, 2016Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab
The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …
Bayer, Regeneron’s Eylea gets additional EU indication
November 2, 2015Research and Development, Sales and Marketing Bayer, Eylea, Regeneron
The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
Sanofi and Regeneron given European nod for Praluent
September 28, 2015Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent
The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent. The heart drug is …
Sanofi and Regeneron in immuno-oncology push
July 28, 2015Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1
Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
Praluent scores positive trial results in Japan
July 9, 2015Research and Development Japan, PCKS9, Regeneron, Sanofi, heart disease, high cholesterol, praluent
Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Bayer and Regeneron eye drug gains another indication
March 26, 2015Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept
Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …
Sanofi and Regeneron post positive alirocumab results
January 9, 2015Sales and Marketing Regeneron, Sanofi, cholesterol, heart, statin, statins
The latest trials of the potentially blockbuster new heart drug alirocumab show it lowers cholesterol in people at moderate and …
Sanofi showcases alirocumab at AHA
November 20, 2014Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab
Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …
Amgen submits next gen cholesterol drug
August 29, 2014Sales and Marketing Amgen, FDA, PCSK9, Regeneron, Sanofi, statins
Amgen has put itself in pole position in the race to market the next generation of injectable statins known as …
Regeneron to expand manufacturing outside US
March 31, 2014Manufacturing and Production Ireland, Regeneron, dell, irish. manufacturing
Regeneron is to open its first overseas production facility in Limerick, Ireland, after addressing the initial objections of a national …
Bayer and Regeneron to co-develop wet AMD antibody
January 14, 2014Research and Development, Sales and Marketing Bayer, Eylea, Regeneron, pdgfr-beta, wet AMD
Bayer and Regeneron are co-developing an antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a combination therapy …
Phase III boost for alirocumab
October 17, 2013Sales and Marketing LDL, Regeneron, alirocumab
Sanofi and Regeneron Pharmaceuticals are celebrating some upbeat data from their investigational treatment alirocumab, which has proved adept at tackling …
Latest content
